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Peptide-based targeting strategies for simultaneous
imaging and therapy with nanovectors
Antonella Accardo, Diego Tesauro and Giancarlo Morelli
Over recent years, multifunctional compounds that combine diagnostic and therapeutic modalities using one unified material
have been developed and designated as theranostics. These compounds provide the chance to develop individually designed
therapies against various diseases to accomplish personalized medicine. In this review, theranostic agents based on nanovectors
(liposomes, naposomes, micelles, polymeric micelles and micelles built around a solid core) externally modified with targeting
peptides able to simultaneously carry a drug and a contrast agent are described, demonstrating that peptide-modified
nanovectors can selectively carry a drug to target cells with an imaging probe co-incorporated into the nanovector
to monitor therapy.
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INTRODUCTION
Cancer remains one of the leading causes of mortality worldwide,
affecting more than 10 million new patients every year. Currently,
treatment options include surgical resection, radiation, and che-
motherapy. Although more than 90 chemotherapeutic drugs have
been approved by the Food and Drug Administration (FDA) for
clinical use, their efficacy has been severely hindered due to dose-
limiting toxicity and patient morbidity. In many cases, a large amount
of the administered drug is also delivered to normal tissue, which
could cause the severe side effects that patients often experience.1
Therefore, an essential approach for overcoming this crucial obstacle
is the development of optimized and targeted delivery systems.2 The
overexpression of specific receptors has been documented for a variety
of cancers. As many as 105–106 receptor molecules per cell or receptor
densities in the pmolmg1 protein range have been reported for a
variety of systems, such as transferrin receptors in hematologic and
other malignancies, somatostatin receptors in neuroendocrine
tumors, CCK2 receptors in medullary thyroid cancer, bombesin
receptors in prostate and breast carcinoma and several others.3–5
Consequently, the conjugation of drugs or contrast agents with
receptor-binding molecules can selectively increase their adherence
to or uptake by target cells.6–9 For this purpose, various targeting
molecules, such as antibodies (Ab), antibody fragments, peptides,
nucleic acid (DNA/RNA aptamer) small molecules, or others
(vitamins or carbohydrates), have been used for target-selective
therapeutic and/or diagnostic applications. Antibodies with two
epitope-binding sites in a single molecule offer remarkably high
binding affinities and selectivities for the target of interest. Several
examples of antibodies approved by the FDA for therapeutic use are
rituximab (Rituxan) for non-Hodgkin’s lymphoma treatment,10
trastuzumab (Herceptin) for breast cancer treatment,11 bevacizumab
(Avastin) to inhibit angiogenesis,12 and cetuximab (Erbitux) for
colorectal cancer treatment.13 Currently, seven human monoclonal
antibodies mAbs have been approved in the United States and in the
European Union, and many others are in clinical development.
Adalimumab, specific to tumor necrosis factor (TNF), was the first
human mAb approved by the FDA in 2002.14 Aptamers are small
nucleic acid ligands (15–40 bases) that can bind specifically to targets
due to their ability to fold into unique conformations with three-
dimensional structures.15 Pegaptanib, a VEGF165-targeted aptamer,
was approved by the FDA in 2004 for the treatment of neovascular
macular degeneration, while AS1411, a nucleolin-targeted aptamer, is
in phase II of clinical development.16–18 Although aptamers and
monoclonal antibodies (mAbs) have been widely used as escort
molecules for the targeted delivery of nanoparticles, they possess
several unfavorable properties. Aptamers have rapid blood clearance,
largely due to nuclease degradation. To overcome this difficulty,
pyrimidine modifications at the 20-fluorine position or chemical
modifications with PEG have been used to enhance the bioavailability
and the pharmacokinetic properties.19 On the other hand, mAbs are
expensive to manufacture and present some degree of variation from
batch to batch. Moreover, the development of targeted mAb
nanoparticles is limited by the large antibody size and by the
difficulty in conjugating mAbs to nanoparticles. Thus, other
smaller-sized ligands, including peptides, have recently attracted
more attention. Currently, several peptides, such as cilengitide (a
cyclic peptide able to selectively recognize integrin receptors) and
adnectin (Angiocept for human VEGF receptor 2), are in clinical trials
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for the treatment of non-small cell lung cancer and pancreatic
cancer20 and for the treatment of advanced solid tumors and non-
Hodgkin’s lymphoma.
Peptides present some drawbacks and advantages compared with
antibodies in their use as targeting molecules. The drawbacks are
related to a low target affinity and metabolic instability due to
enzymatic degradation. Strategies to improve the metabolic stability
and pharmacokinetics could be based on the modification of the
peptide sequence, such as the introduction of D-amino acids or
multivalent sequences. Peptide advantages consist of their low
immunogenicity, low cost, stability, long-term storage and easy
handling.21 Furthermore, the associated risks from unintended
effects on the host immune system is low, and their small size is
less likely to change the optimized physicochemical properties of
nanoparticles.22 Peptide-based targeting ligands can be identified via
several methods. Most commonly, they are obtained from the binding
regions of the protein of interest or from modeling new sequences on
the structure of the target receptor. Phage display techniques can also
be used to identify peptide-targeting ligands.
In recent years, the idea of combining several functions in the same
compound has gained popularity. For example, researchers realized
that the complementary abilities of different imaging modalities could
be utilized to great effect by using the modalities together.23,24 In fact,
no single imaging modality currently provides the combination of
sufficiently high sensitivity with a high spatial and temporal
resolution. Many hybrid systems that combine two or more of
these imaging modalities, such as PET (positron-emission
tomography) and SPECT (single-photon-emission computed
tomography) in combination with CT (computed tomography)
and/or MRI, are commercially available and others are under active
development.25 Moreover, for the nuclear imaging techniques PET
and SPECT, radioactive tracers are used; they provide information in
a sensitive, non-invasive, and quantitative manner. Just as multiple
species of imaging probes can be combined in a single compound,
molecules with therapeutic functions can be incorporated, thus
yielding probes with combined therapeutic and diagnostic
functions. The goal is to use imaging probes as tools to guide or to
monitor therapy. The term ‘theranostic’ was recently coined to
describe multifunctional compounds that are able to combine
diagnostic and therapeutic modalities in one unified material,
providing the chance to develop individually designed therapies
against various diseases to accomplish personalized medicine.26
A theranostic nanomedicine approach could improve personal
medicine by means of several essential issues: (i) the optimization of
drug delivery systems via a noninvasive assessment of the pharma-
cokinetics, biodistribution and target site localization of conjugated or
entrapped pharmacologically active agents; (ii) the prediction of
treatment responses by combining information on the overall target
site localization with noninvasive imaging insights into the local
distribution of the drug and/or of the carrier material at the target
site; (iii) defining the efficacy of drug delivery systems by using
contrast agents to monitor the release of pharmacologically active
agents from stimuli-sensitive nanomedicines. In other words, ther-
anostic systems providing real-time feedback on the efficacy of
targeted therapeutic interventions could be used to facilitate pre-
clinical efficacy analysis, to prescreen patients, and to generate
optimal clinical treatments for each patient.27 It can be reasoned
that treatment should be continued only for patients who show high
levels of target site uptake and that for those patients in whom this is
not the case, other therapeutic options should be considered. In the
present review, we focused our attention on target-selective
theranostic agents based on nanovectors that are able to carry,
simultaneously, a drug and a contrast agent and that are externally
modified with targeting peptides (see Table 1).
NANOSYSTEM-BASED THERANOSTICS
Recently, nanoscopic (10–500 nm) systems, such as polymeric
micelles, polymer-drug conjugates, dendrimers, liposomes, and inor-
ganic particulates, that incorporate therapeutic agents, molecular
targeting, and diagnostic imaging capabilities are emerging as the
next generation of multifunctional nanomedicines for improving the
therapeutic outcome of drug therapy.28–31
Several authors have highlighted the importance of using targeted
nanoparticles, which are functionalized with antibodies, peptides,
Table 1 Peptide, receptor system, therapeutic and diagnostic agent for each described theranostic nanostructure are reported
Nanosystem Peptide Receptor Therapeutic agent Diagnostic agent Ref.
Liposomes cRGDfK integrin avb3 Dox BODIPY 45
CSNIDARAC integrin avb6 Dox Cy7.5 47
CCK8 Cholecystokinin Dox 111In-DTPAGlu 58
[7–14]BN GRP Dox 111In-DTPA 60
Polymeric Micelles (PM) GRGDS-NH2 integrin avb3 MTX Gd MOF 64
cRGD integrin avb3 Dox 64Cu-NOTA 65
CRKRLDRNC IL-4 Dox Cy5.5 68
Iron oxide nanoparticles F3 nucleolin Photofrin Iron oxide 70
cRGD integrin avb3 Dox SPIO 72
RGDLATLRQL integrin avb6 Dox SPIO 73
RGD integrin avb3 PAV Iron oxide/Cy7 74
CREKA/CRKDKC — — SPIO/Cy7 76
CGKRK GBM D[KLAKLAK]2 Iron oxide 77
CTX /Brain siRNA Iron oxide 79
EPPT uMUC-1 siRNA SPION/Cy5.5 81
Gold Nanoparticles tTF-RGD integrin avb3 Dox/Gold-NRs SPIO 82
Quantum dots cRGD integrin avb3 Dox QD 86
Mesoporus silica cRGDyK integrin avb3 PdTPP ATTO647N 87
particles SP94 — Dox Calcein/Alexa QDs/fluor 647 dsDNA/RFP 88
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aptamers and small organic molecules, for cancer therapy and
diagnosis.27,32,33
In cancer therapy, nanosystems exhibit several potential advantages
with respect to conventional small molecule-based therapy.34 They
present a high payload capacity, reduced toxicity to healthy tissue, and
improved antitumor efficacy. When intravenously injected, particles
smaller than 5 nm are removed from the blood by rapid renal
clearance through the kidneys, while large microsized particles are
filtered mechanically by the sinusoids and cleared by the reticulo-
endothelial system (RES) of the liver and spleen.35 Moreover, due to
the incomplete tumor vasculature (vessels with enlarged gap junctions
of 100 nm to 2mm), nanosystems can selectively extravasate into
tumor tissue more rapidly than drugs with lower molecular weights
and can remain there for an extended period of time (days to
weeks).36,37 This phenomenon, identified as ‘enhanced permeability
and retention (EPR) effect’, was developed by Maeda and colleagues38
and represents a form of selective delivery termed ‘passive targeting’.
Therefore, nanoparticles 10–500 nm in size can remain in circulation
for an extended period of time when injected intravenously and can
be employed in strategies for targeted delivery, such as passive or
active targeting.39 Moreover, ‘active targeting’ is realized by using
nanoparticles externally modified with targeting molecules, such as
antibodies or peptides.
LIPOSOMES
The most popular and clinically established nanometer-scale drug
carriers are liposomes and micelles. Liposomes are used to deliver
cytotoxic and antifungal drugs, genes, and vaccines, as well as imaging
agents.40 They are unilamellar or multilamellar phospholipid vesicles
with an aqueous phase inside and with a size ranging from 50–
500 nm. Liposomes offer several advantage compared with traditional
delivery systems. Liposomes are easily prepared from commercial or
synthetic phospholipids; moreover, their external surfaces can be
modified by simply adding a chemical functional group. The ability to
easily manipulate their sizes and surfaces leads to the outstanding
advantages that liposomes offer over other delivery systems. Lipo-
somes are excellent carriers for drug delivery; hydrophilic drugs can
be encapsulated in the inner aqueous compartment while poor-
soluble drugs can be solubilized in the phospholipid bilayer. The
encapsulation of cytotoxic and/or cardiotoxic drugs in liposomes
modifies their tissue distribution and their pharmacokinetics. For
example, the conventional drug doxorubicin (Dox) is an established
cytotoxic agent for many cancer types, in particular for breast and
ovarian cancer, and its use has been shown to be clinically effective.
However, irreversible cardiac toxicity has been a primary dose-
limiting factor in the use of this drug. A successful strategy for
reducing the cardiac toxicity associated with Dox involves its
encapsulation in liposomes, which alters the tissue distribution and
the pharmacokinetics of this drug while maintaining the efficacy and
improving the therapeutic index.41,42 Liposomal doxorubicin
formulations (for example Myocet and Caelyx/Doxil) have shown
reduced cardiac toxicity compared with free Dox while preserving the
antitumor efficacy.43,44 An example of liposomal doxorubicin
decorated with a cyclic RGDfK peptide for imaging and for treating
a metastatic disease was reported by Cheresh et al.45 This peptide
sequence selectively recognizes the avb3 integrin receptor
that is expressed on angiogenic endothelium.46 RGD liposomes
(DSPC/Chol/DOPE/DSPE-mPEG2000/DSPE-cyclic RGDfK) were
formulated using standard preparation procedures, and Dox was
encapsulated via remote loading at 55 1C to produce RGD-Dox-NPs.
Moreover, the liposomes were made fluorescent by the insertion of
1% of the fluorophore DOPE-BODIPY 630/650. The in vivo binding
ability and tumor efficacy of the RGD-Dox-NPs (targeted NPs) with
respect to RAD-Dox-NPs (RAD is a control peptide with the cRADfK
sequence) were determined using mice bearing the basic fibroblast
growth factor (bFGF). An apoptotic effect was observed only for the
targeted NPs, and, in particular, the authors observed a reduction in
the primary tumor growth (23%) and a significant reduction in
metastasis (82%) in an orthotopic pancreatic tumor model that
included metastatic lesions in the hepatic hilar lymph node 7 days
after injection.
Theranostic liposomal Dox was also studied by Lee and
colleagues47 for the imaging of doxorubicin at and the targeted
delivery of doxorubicin to a lung tumor. Lung cancer is the leading
cause of death due to cancer, and its high mortality rate appears to be
derived from a low therapeutic index for chemotherapy and from late
detection due to a lack of sensitive diagnostic biomarkers. The
identification of novel biomarkers for early lung cancer detection
remains a challenge. In this study, a novel peptide (CSNIDARAC)
with a high binding affinity for lung tumors was identified by the
in vitro screening of a phage display peptide library, and CSNIDARAC
peptide-conjugated liposomal Dox (Lipo-Dox) was synthesized. The
in vivo tumor targeting capabilities and the therapeutic efficacy were
evaluated using the H460 tumor xenografted into mice. To minimize
the interactions between the targeted peptide and the surface of the
liposome, the amount of PEG on the surface of the liposome was
reduced from 5–20mol% (general use) to 1.3mol% of the total lipids.
The tumor growth inhibition of the peptide-targeted Lipo-Dox was
superior to that of the untargeted Lipo-Dox and to that of the free
Dox administered at equivalent doses (2mg of doxorubicin/kg of
body weight), and this result was consistent with the levels of
apoptosis measured by TUNEL staining. Near-IR Cy7.5 dye-labeled
peptide-conjugated Lipo-Dox also showed a distinct fluorescence
signal at the tumor, while the untargeted Lipo-Dox did not show
strong signal intensity.
NAPOSOMES
Recently, Morelli and colleagues developed ‘naposomes’, multimodal
nanoparticles with their external surfaces functionalized by neuroen-
docrine peptide sequences and that encapsulate both anticancer drugs
and metal complexes.48,49 Naposomes were obtained by combining an
amphiphilic monomer which contains a hydrophobic moiety, a PEG
spacer and a peptide, with another monomer based on the same
hydrophobic moiety with a chelating agent for metal complexation.
Bioactive peptides chosen for naposome assembly (CCK8,50,51 7–14-
bombesin (BN)52–54 and octreotide55–57) are well-known endogenous
(CCK8 and BN) or artificial (octreotide) ligands for membrane
receptors (cholecystokinin, GRP and somatostatin) that are
overexpressed by the cells of several human cancers. Chelating
agents, such as DOTA, DTPA and DTPAGlu, are employed to stably
complex paramagnetic or radioactive metals for imaging with MRI,
PET tomography and scintigraphy (Figure 1). The morphology of
aggregates (micelles, liposomes or an open bilayer) is strictly
dependent on the starting monomers (the metal complex and/or
peptide sequence). The uptake of 111In-radiolabeled naposomes by
A431 cells overexpressing CCK2-R via transfection was demonstrated
by in vitro experiments at 4 1C and at 37 1C.58 The in vivo
biodistribution showed that the overall retention of the radiolabel
aggregates in the mice at 18 h is very high, with essentially no
excretion of radioactivity over the observation period. Moreover, the
radioactivity retention of the receptor-positive xenografts was always
higher than in their respective controls (Figure 1). Finally, in vitro
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Figure 1 (a) Amphiphilic monomers (one containing a peptide moiety and the other containing the chelating agent) and the supramolecular aggregates that
can be obtained when the monomers are combined at the chosen molecular ratio in a water solution. The hydrophobic moieties, present on both monomers,
are based on two saturated hydrocarbon chains with 18 carbon atoms. In the two frameworks, the peptide sequences (Octreotide, Bombesin and CCK8) and
the structure of the chelating agents used for naposome preparation are reported. The lower part of the figure shows selected results from structural and
biological studies on the naposomes labeled with the CCK8 peptide. (b) The g-camera image (dorsal view) obtained prior to the dissection of one of the
animals 18 h after injection of the radiolabeled aggregates clearly shows a higher concentration of the radiolabel in the receptor positive xenograft (þ , left
flank) than in the control tumor (, right flank). These differences were statistically significant when comparing data from the five animals (paired t-test,
P¼0.01). (c) The cytotoxicity of liposomal Dox against human carcinoma cells. The A431 cells were incubated with CCK8/DOTA-Dox and with DOTA-Dox at
different concentration ranging between 0 and 1000 ngml1 at 37 1C. After 8 h, the medium was removed, and after an additional 72 h an MTT assay was
performed.
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cytotoxicity assays were performed by incubating the cells with
peptide-containing aggregates filled with Dox. Cell survival in the
receptor-expressing cells was significantly lower than in the control.
(C18)2DOTA/(C18)2L5CCK8 (90/10) liposomes showed comparable
results.59
Very recently, the same authors described new BN-conjugated
nanosystems for theranostic purposes.60 The liposomes are based on
the co-aggregation of a DSPC phospholipid with MonY-BN, a new
synthetic amphiphilic monomer (Figure 2) containing a 7-14-Bombe-
sin peptide fragment, DTPA chelating agent, hydrophobic moiety with
two C18 alkyl chains, and PEG spacers. 111In-labeled liposomes loaded
with doxorubicin (DSPC/MonY-BN in a 97/3 molar ratio) showed a
higher specific binding to PC-3 (prostate cancer) cells than the peptide
free DSPC liposomes (2.7±0.3 and 1.4±0.2%) and showed signifi-
cant growth inhibition at drug amounts of 100 ngml1 and
300ngml1. Moreover, the intravenous treatment of PC-3 xeno-
graft-bearing mice using targeted liposomes and untargeted liposomes
at a 10mg kg1 Dox dose produced a higher tumor growth inhibition
(60 and 36%, respectively) compared with the control animals.
POLYMERIC MICELLES
Large proportions of new drug candidates emerging from high-
throughput drug screening initiatives are water-insoluble. To
overcome the poor solubility of certain drugs, the development of
pharmaceutical carriers such as micelles and polymeric micelles was
suggested.
Polymeric micelles are nanosized particles obtained from the self-
assembly of biocompatible amphiphilic block copolymers in aqueous
solution.61 Their characteristic feature is a pronounced core-shell
architecture, which can be controlled by the individual polymer
blocks. The core of polymeric micelles is typically obtained from a
hydrophobic segment that consists of biodegradable polyesters, such
as poly(glycolic acid), poly(D,L-lactic acid) (PDLLA), poly(e-
caprolactone) (PCL), and poly(L-aspartic acid).62 Additionally, the
largely used corona forming polymer is polyethylene glycol (PEG),
with a molecular weight ranging from 2 to 15 kDa. The hydrophobic
core represents an ideal carrier environment for poor water-soluble
drugs while the hydrophilic shell provides interactions with the
solvent, protecting the hydrophobic core from the aqueous bulk
phase. The hydrodynamic radius of polymeric micelles, usually
ranging between 10 and 100nm, can be controlled by varying the
hydrophobic block of the copolymer.63
An example of theranostic micelles that can be used for tumor
treatment and for MRI detection was successfully obtained by Boyes
and colleagues through the attachment of well-defined, multifunc-
tional polymer chains to gadolinium metal-organic framework
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Figure 2 (a) Schematic representation of MonY-BN. The 7-14-BN peptide sequence is reported using the three-letter amino acid code. (b) The cytotoxicity
of liposomal Dox against human prostatic cancer cells. The PC-3 cells (8000cells per well) were incubated with DSPC/MonY-BN/Dox, DSPC/Dox and free
Dox at 37 1C. The control experiments with free Dox and empty liposomes at the same experimental conditions are reported. After 8 h, the medium was
removed, and after an additional 72 h an MTS assay was performed. (c) Comparative efficacy study on the tumor growth in BALB/c nude mice bearing
xenografts (PC-3). Treatment started approximately 5 weeks after cell implantation. Mice (n¼5) were administered with i.v. injections of 100ml of the
liposome suspensions of DSPC/MonY-BN/Dox or DSPC/Dox or with 100ml of HBS buffer (control). The therapeutic efficacy was assessed by measuring the
tumor volume (mean±s.d.) over time. DSPC/MonY-BN/Dox and DSPC/Dox produce, respective to the saline solution, a tumor growth inhibition (TGI) of 60
and 36%, respectively. ’Reprinted from Reference 85, Copyright (2012), with permission from Dove Medical Press Ltd.’
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(MOF) nanoparticles. Gd MOF nanoparticles were surface modified
by the covalent attachment of well-defined polymers containing both
a targeting peptide (GRGDS-NH2) and the antineoplastic agent
methotrexate (MTX) to produce a novel theranostic nanodevice.64
To evaluate the potential of the copolymer-modified nanoparticles for
use as a theranostic nanodevice, MRI, fluorescence imaging, and cell
growth inhibition studies were performed. In the MRI studies, the T1
relaxation times of the polymer-modified Gd MOF nanoparticles are
on the same order of magnitude as those of the conventional clinically
used Gd contrast agents. Copolymer-modified Gd MOF nanoparticles
containing the targeting moiety GRGDS-NH2 showed active targeting
of FITZ-HSA tumor cells, which overexpress avb3 integrins. The Gd
MOF nanoparticles modified with the copolymer containing MTX
showed a dose-dependent treatment of FITZ-HSA cancer cells,
determined by cell viability measurements.
Very recently, multifunctional micelles decorated with the cRGD
peptide were also investigated for PET imaging by Gong and
colleagues. They synthesized and characterized multifunctional unim-
olecular micelles made from hyperbranched amphiphilic block
copolymers [H40-P(LG-Hyd-Dox)-b-PEG] conjugated with the
cRGD peptide and with the macrocyclic chelator NOTA for cancer-
targeted drug delivery and for PET imaging.65 In the multifunctional
micelles, the anticancer doxorubicin drug is bound to the
hydrophobic poly(L-glutamate) segment P(LG-Hyd-Dox) with a
hydrazone linkage. This acid-labile linkage provides a pH-controlled
drug release behavior for the micelles. The active tumor targeting
ligand (cRGD) and the PET isotope chelator NOTA were conjugated
onto the PEG arms. From a biological point of view, the cytotoxicity
assays showed a higher cellular uptake in the U87MG human
glioblastoma cells of the target selective micelles (H40-Dox-cRGD)
than in the cells of the non-targeted micelles (H40-Dox). Moreover,
in vivo studies of tumor-bearing mice confirmed that H40-Dox-
cRGD-64Cu exhibited a much higher level of tumor accumulation
than H40-Dox-64Cu, as measured by non-invasive PET imaging and
by ex vivo fluorescence imaging.
Polymeric micelles were also used for the detection of an athero-
sclerotic lesion by Rhee K and colleagues. They developed hydro-
phobically modified chitosan nanoparticles (CNPs) chemically
conjugated with an atherosclerotic plaque-homing peptide
(CRKRLDRNC; AP peptide) and with Cy5.5, a near-infrared (NIR)
probe. The AP peptide, discovered using an in vivo phage display
screening method,66 could adhere to atherosclerotic plaque by
binding to the interleukin (IL)-4 receptors on the macrophages,
endothelial cells, and smooth muscle cells. The conjugated CNPs
demonstrated a higher binding affinity to the tumor necrosis factor
(TNF)-R-activated bovine aortic endothelial cells (BAECs) than to the
non-activated BAECs.67 Moreover, in vivo NIRF imaging data
revealed that larger amounts of the APCy5.5CNPs were bound to
atherosclerotic lesions in the atherosclerotic mouse that lacks the low-
density lipoprotein receptor than to the same lesions in a normal
mouse (Figure 3). Additionally, the same authors prepared pH-
responsive polymeric micelles (AP-pH-PMs) decorated with the AP
peptide and loaded with the chemotherapeutic agent doxorubicin for
breast cancer disease. The micelles were made fluorescent by adding a
small amount of a fluorescent dye (TRITC) into their composition.
This modification was utilized to evaluate in vitro and in vivo the
binding capability of the AP-pH-PMs with respect to the MPEG-PAE,
where the peptide is absent. The in vivo cytotoxicity studies on the
MDA-MB231 human breast tumor-bearing mice demonstrated the
excellent anticancer therapeutic efficacy of the targeted Dox-AP-pH-
PMs with respect to the free Dox and to the Dox encapsulated MEG-
PAE micelles.68
POLYMERIC MICELLES WITH A SOLID CORE
Most polymeric micelles are constructed around a solid core, which
display unique properties for the stability and/or the detection of the
Figure 3 Design strategy of a peptide-conjugated pH-responsive micelle. (a) Chemical structure of the tumor-targeting AP peptide coupled PEG-PLA block
copolymer (AP-PEG-PLA) and (b) of the pH-responsive MPEG-PAE block copolymer (MPEG-PAE). (c) Schematic diagram depicting tumor-targeting and
pH-responsive polymeric micelles of AP-PEG-PLA/MPEG-PAE (AP-pH-PM), which triggered Dox release due to the sharp pH-dependent micellization/
demicellizaton transition at the tumoral acidic pH. (d) In vivo fluorescence images of MDA-MB-231 tumor xenografted athymic nude mice injected with
TRITC-pH-PM and with TRITC-AP-pH-PM. (e) In vivo anti-tumor therapy of doxorubicin encapsulated micelles: in vivo anti-tumor therapeutic efficacy of
saline (&), pH-PM (J), AP-pH-PM (D), free Dox (2mgkg1) (’), Dox- pH-PM with 2 mg kg1 of Dox (K), and Dox-AP-pH-PM with 2 mgkg1 of Dox (m).
Values represent the mean±s.d. and the tumor weights of MDA-MB-231 tumor-bearing mice 15 days post-treatment. Reproduced with permission from the
publisher [68].
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system. Core nanoparticles, typically ranged between 5 and 100 nm in
diameter, and nanoparticles of many different shapes and composite
formulations have been developed. The most extensively studied core
nanoparticle materials are based on metals, such as gold, silver, iron,
cobalt, nickel and platinum. Nanoparticles such as iron oxide,
quantum dots, and gold are known to offer extraordinary features
for diagnostics as well as for therapeutics. Imaging modalities, such as
optical imaging, MRI, and surface plasmon resonance (SPR), are
rapid, noninvasive techniques that have been used in cancer therapy
where the early detection and disease prognosis need to be improved.
IRON OXIDE NANOPARTICLES
Iron oxide nanoparticles are clinically approved MRI contrast agents
and have also been proposed as a platform for the development of
targeted contrast agents because they have a large surface area that can
be functionalized with different targeting ligands, their blood
circulation can be modulated according to their physicochemical
properties, and contrast agents and drugs can be included at
predetermined ratios either in the interior or on the surfaces of the
nanoparticles.
One of the first examples of polymeric micelles with an iron oxide
core was reported by Ross and colleagues in 2006 as a versatile drug
delivery vehicle for the supply of imaging and therapeutic agents to a
brain cancer milieu. The authors prepared nanoparticles based on a
polyacrylamide (PAA) nanoparticle core that combine a magnetic
resonance imaging contrast enhancement, photodynamic therapy
and specific targeting to tumor sites by using the F3 vascular homing
peptide. The F3 peptide, a 31-amino acid fragment of a high mobility
group protein, was shown to home in on the vasculature of a number
of tumor types by directly interacting with endothelial cells.69 The
F3-targeted polymeric nanoparticle formulation consists of
encapsulating iron oxide or a fluorescent probe and a Photofrin
photosensitizer.70 This formulation was evaluated using a series of
in vitro experiments to study its ability to produce singlet oxygen, to
target the nucleolin cell surface receptor, and to confer photo-
sensitivity. The in vitro studies revealed that the F3-targeted nano-
particles were bound, internalized, transported, and concentrated
within the tumor cell nuclei. Photoactivation of the nanoparticles
resulted in the loss of cell viability. The in vivo studies revealed that
iron oxide/Photofrin-encapsulated F3-targeted nanoparticles could
Figure 4 (a) Schematic of a multifunctional polymeric micelle. (b) and (c) Pre- and post-contrast coronal images of tumor-bearing mice by T2-weighted
imaging (TR/TE¼4 s/40 ms), respectively. (d) and (e) Bioluminescence imaging of a mouse bearing luciferase-transfected H1299 xenograft at days 0 and 7,
respectively. Dox-loaded, 16% cRGD-micelles were injected into the tail vein at days 0 and 3 (4 mgkg1 Dox dose each time). (f) Antitumor efficacy data
for the PBS control and Dox-SPIO micelles with 0 and 16% surface density of cRGD in subcutaneous A549 tumor xenografts in nude mice. Each data
point is averaged from three animals. Copyrightª Experimental Biology and Medicine.
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be detected in i.c. 9L gliomas using MRI. Treatment of glioma-
bearing rats with the F3-targeted nanoparticles followed by
photodynamic therapy (PDT) showed a significant improvement in
the survival rate when compared with animals that received PDT
after administration of the non-targeted nanoparticles or of systemic
Photofrin. In this formulation, the micelles homed in on the
vasculature of a number of tumor types through the interaction of
the F3 peptide with endothelial cells. This peptide exhibits two
attractive features compared with the RGD containing peptide: (1)
the RGD peptide needs to be cyclized to be functional, which is not
optimal for large scale studies, while the F3 peptide does not have
this requirement. (2) In some human cancers, the F3 peptide can
interact directly with the tumor cells, where it is specifically taken up
at the cell surface, internalized into the cell and transported to the
nucleus. Cell surface nucleolin is a specific marker for angiogenic
endothelial cells within the tumor vasculature. Nevertheless, many
authors chose to functionalize theranostic nanoparticles with RGD or
with RGD analogs due to their capability to selectively recognize avb3
integrin receptors on angiogenic endothelial cells that are
overexpressed in many solid tumors (colon cancer, brain cancer,
prostate cancer and others).
For example, in 2006 Gao and colleagues developed multifunc-
tional polymeric micelles decorated with cRGD (cRGD-DOXO-SPIO)
with a cancer-targeting capability for controlled drug delivery and for
efficient MRI contrast characteristics. These micelles are composed of
the chemotherapeutic agent DOXO, which is released from polymeric
micelles through a pH-dependent mechanism, and of a cluster of
super paramagnetic iron oxide (SPIO) nanoparticles (8 nm in
diameter). SPIO and DOXO were loaded into the polymeric micelles
at 6.7 and 2.7 w/w%, respectively. Amphiphilic block copolymers of
MAL-PEG-PLA and MPEG-PLA were used for micelle formation.
Different amounts of MPEG-PLA were used to control the density of
maleimide, which ultimately determined the density of cRGD on the
micelle surface (0 and 16% for all PEG chains). In vitro imaging of the
multifunctional micelles was evaluated using avb3-expressing SLK
tumor endothelial cells (derived from human Kaposi’s sarcoma) by
MRI, by flow cytometry and by confocal laser scanning microscopy.
Moreover, cRGD micelles showed a higher cell growth inhibition than
the untargeted micelles.71 The tumor targeting, imaging ability, and
antitumor efficacy of the multifunctional micelles were validated
using in vivo assays (Figure 4). For the antitumor efficacy in the
orthotopic H1299 tumor model, bioluminescent imaging (BLI) of
tumors transfected with the firefly luciferase gene was used.
A comparison between the target selective and untargeted SPIO
micelles showed a size reduction in the tumor of approximately 50%
after 7 and 10 days, respectively. In the mice treated with the PBS
control group the tumor size almost doubled after 10 days.72 In a
separate study, these multifunctional micelles (MFM, formed by
MAL-PEG-PLA and MPEG-PLA copolymers, 75% by weight)
containing Dox and SPIO were decorated with a RGDLATLRQL
(LCP) peptide, which binds specifically to the avb6 receptors that are
overexpressed in lung cancer cells. Different surface densities were
obtained by varying the molar fraction of MAL-PEG-PLA between 20
and 40%. The selective binding ability of the LCP peptide to the avb6
receptors with respect to MFM derivatized with a scrambled peptide
(SP) sequence was evaluated using comparative exposures of H2009
cells studied using [3H] radioactivity measurements, confocal
microscopy and MRI. avb6-negative H460-cells were used as a
control. The resulting LCP-encoded MFM showed a superb T2
relaxivity for ultrasensitive MR detection and an increased
cytotoxicity in H2009 cells compared with the SP-encoded MFM.73
As an alternative, theranostic nanoparticles based on oil-in-water
nanoemulsions and functionalized with the avb3-specific RGD
peptide were developed and evaluated in a colon cancer mouse
model. The nanoparticles (PEG-DSPE:DSPC:MAL-PEG-DSPE molar
ratio 0.83:1:0.1) contained iron oxide nanocrystals for MRI, the
fluorescent dye Cy7 for NIRF imaging, and the hydrophobic
glucocorticoid prednisolone acetate valerate (PAV) for therapeutic
purposes. in vitro and in vivo assays confirmed that the angiogenesis-
targeted nanoemulsions showed efficient tumor growth inhibition
with respect to the untargeted nanoemulsions.74
Ruoslahti and colleagues described a self-amplifying nanoparticle-
delivery system (nanomag-D-SPIO) functionalized with tumor-hom-
ing pentapeptide CREKA (Cys-Arg-Glu-Lys-Ala)75 for the effective
detection of tumors in prostate blood vessels.
The CREKA peptide exposed on the nanoparticles (DSPC/Chol/
DOGS-NTA at a molar ratio of 57:37:10) recognizes the clotted
plasma proteins near tumor vessel walls or the tumor stroma and
induces localized tumor clotting. Additionally, they reported a study
on elongated nanoworms (NW) coated with another tumor-homing
peptide, CRKDKC. The same authors prepared a nanosystem
functionalized with the N/Ca-methylated CREKA peptide
(CR(NMe)EKA) to increase the stability of the peptide in circula-
tion.76 Mice bearing two orthotopic human prostate cancer xenograft
tumors (22Rv1 and LAPC29) were treated with the nanoworms. Mice
treated with the targeted nanoworms showed extensive clotting in the
tumor vessels, while no clotting was observed in the vessels of normal
tissue. Diagnostic studies performed using optical and magnetic
resonance imaging confirmed the ability of the targeted nanoworms
to accumulate on the tumor vessels, and ultrasound imaging showed
a reduced blood flow in the tumor vessels. In vivo studies carried out
on mice with prostate cancer demonstrated that both CRKDKC-PEG-
NW and CR(NMe)EKA-PEG-NW are able to induce tumor necrosis
(B70%) when treated with multiple doses.
NWs were also proposed for transient tumor regression in
glioblastoma multiforme (GBM) endothelium.77 Treatment of
malignant brain tumors is one of the most formidable challenges in
oncology due to the difficulties associated with drug delivery across
the BBB to the tumor. The brain tumor endothelium, with
characteristics such as a high proliferation, high permeability, and
high expression of proangiogenic factors, can be treated with
antiangiogenic approaches.78 These nanosystems combined three
different functions: (i) the CGKRK peptide able to specifically
target the mitochondria of the tumor endothelial cells and tumor
cells, (ii) the D[KLAKLAK]2 proapoptotic peptide that acts on the
mitochondria, and (iii) iron oxide nanoparticles, which enhance the
proapoptotic activity. Moreover, with the help of a tumor penetrating
peptide (iRGD), the NWs were capable of infiltrating the tumor tissue
for tumor cell eradication after extravasation. This strategy was
evaluated in the lentivirus-induced, transplantable, and orthotopic
brain tumor models. The tumor accumulation and the binding
capability of the single peptide was not compromised by the
chimeric NWs composed of the CGKRK and D[KLAKLAK]2
peptides. Complete tumor ablation was achieved in the first model
and the significant prolongation of survival was observed in the latter
two models, indicating promise for eventual clinical application.
In vivo brain tumor targeting was also achieved by Zhang and
colleagues using a magnetic/optical nanoprobe with the chlorotoxin
(CTX) peptide.79 CTX shows strong affinity for tumors of neuro-
ectodermal origin and is able to permeate across an intact BBB.80
Superparamagnetic iron oxide nanoparticles coated with oleic acid
and with PEG (NP-SH) were modified with an amine group-blocked
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polyethyleneimine (PEI) to act as a pH-sensitive coating layer. Both
anti-GFP siRNA and CTX were immobilized onto the NPs as a
therapeutic moiety and as a targeting ligand for glioma, respectively.
In vitro studies carried out on C6 glioma cells demonstrated that the
nanoprobes decorated with CTX only possess significant cytotoxic
activity and gene silencing effects at acidic pH conditions.
Another example of polymeric micelles built around iron oxide
(cross-linked dextran-coated superparamagnetic iron oxide nanopar-
ticles) was reported by Medarova and colleagues They synthesized a
nanoshuttle functionalized with EPPT peptides (MN-EPPT-siBIRC5)
for the specific delivery of a synthetic siRNA to the tumor-specific
antigen underglycosylated mucin-1 (uMUC-1), which is found in
490% of human breast adenocarcinomas. In this nanoshuttle, there
are two diagnostic agents: SPIONs for tumor detection by MRI and
the Cy5.5 dye for near-IR optical imaging.81 This therapeutic and
diagnostic nanodrug exhibited superparamagnetic and fluorescence
properties and was simultaneously imaged in vivo by T2 MRI and by
near-IR optical imaging. The systemic administration of the nanodrug
once a week for 2 weeks induced considerable levels of necrosis and
apoptosis in the tumors as a result of the siBIRC5-mediated
inhibition of the antiapoptotic survivin proto-oncogene, which
translates into a significant decrease in the tumor growth rate. This
tumor-targeted, imaging-capable nanodrug highlights the potential
for MRI-guided tumor treatment, which can be used to quantify
changes in the tumor volume over the treatment schedule and to
guide the selection of an optimal treatment course.
GOLD NANOPARTICLES
Gold nanoparticles have been utilized extensively because of their easy
detection by electron microscopy, their SPR properties, and their
photothermal effects.
Bhatia and colleagues designed communicating nanosystems using
‘signaling’ modules (gold nanorods, NRs; or the tumor-targeted tissue
factor, tTF) as selective tumor-activating agents and using ‘receiving’
nanoparticles (magnetofluorescent iron oxide nanoworms, NWs; or
Dox-loaded liposomes, LPs) as targeted imaging or therapeutic
agents.82 NWs, which were previously developed by Bhatia and
colleagues, are elongated nanostructures formed from the assembly
of iron oxide cores that exhibit strong magnetic properties and
efficient tumor targeting.83 The two ‘signaling’ modules specifically
activated the coagulation cascade in the tumor to broadcast the
tumor’s location to the receivers in circulation. The NRs passively
targeted the tumors and converted external electromagnetic energy
into heat to locally disrupt the tumor vessels. The tTF, which included
the RGD peptide motif, induced coagulation upon binding to the
angiogenic avb3 receptors. The receiving nanoparticles targeted the
regions of coagulation. The NWs and LPs were derivatized with a
peptide substrate for the coagulation of transglutaminase FXIII or
with a fibrin-binding peptide. After injecting the signaling modules
into MDA-MB-435 bearing mice at 45 1C, the ‘receiving’ NWs or LPs
indicated prominent extravascular accumulation around the tumor
and amplified the therapeutic outcome, demonstrating a heat-
dependent increase in the passive accumulation and in the specific
biochemical recognition of the coagulation process. Communication
via the coagulation cascade improved the accumulation of the
receiving modules on the tumors by a factor of 40 relative to the
accumulation of the receiving modules without communication.
QUANTUM DOTS (QDS)
Another commonly studied core nanoparticle is the ‘quantum dot’,
named for its unique optical properties and high quantum yield.84
QDs are semiconductor materials consisting of elements from groups
II to VI in the periodic table, such as Cd, Zn, and Se, or from
groups III-V, such as In, P, and As.85 By confining the electrons
to various sizes, the energy band gap, absorption spectra
and corresponding emission wavelengths can be tuned from the
ultraviolet (UV) to the NIR region. The quantum yield of the semi-
conductor (for example CdSe) core is enhanced by the addition of a
shell of a high band-gap semiconductor material, for example zinc
sulfide (ZnS), around the core. The hydrophilicity/hydrophobicity
properties of QDs can be altered by modifying their surfaces. For
example, carboxylic groups on the ZnS shell can be converted into
thiol groups (SH). The exceptional brightness and photostability of
QDs compared with conventional organic dyes as well as the different
emission spectra for quantum dots of the same nanomaterials with
different sizes are the reasons for using QDs as fluorescent
nanosystems for imaging tumors.
QDs emitting in the NIR region and covered by PEGylated
phospholipid micelles were used as optical probes for in vivo imaging
of solid tumors. Target selective nanosystems were obtained by
functionalizing micelles with the cyclic-RGD peptide for target-
specific labeling of tumors in mouse models bearing pancreatic
tumor xenografts, which were implanted both subcutaneously and
orthotopically. Co-encapsulation of both the QDs and anticancer
drugs in the phospholipid micelles were also demonstrated, showing
the potential for engineering theranostic nanoparticles for advanced
biological applications. In vitro viability studies on Panc-1 cells were
performed, treating the cells with the micelles co-encapsulating the
QDs and 2.0 wt% of Dox as well as with the micelles encapsulating
the QDs only (control). The viability of the Panc-1 cells treated with
the drug-loaded particles decreased dramatically, thus confirming the
toxic effect of the Dox released from the particles on the human
cancer cells.86
MESOPOROUS SILICA PARTICLES
Nanoporous silica offers a higher surface area and binding capacity
for therapeutic and diagnostic agents than similarly sized liposomes
and, therefore, provides an attractive drug delivery system. Multi-
component cargos are easily loaded into the nanoporous silica cores,
and the resultant nanocarriers can potentially be used for targeted
multicomponent delivery.
In 2010, Lo and colleagues developed tri-functionalized mesopor-
ous silica nanoparticles (MSNs) for use as theranostic (imaging/
targeting/therapy) compounds.87 The mesoporous silica materials
consisted of highly ordered, hexagonal mesoporous silica structures
with three distinct domains: the silica framework, the hexagonal
nanochannels/pores, and the nanoparticle’s outer surface. The authors
incorporated a near-infrared fluorescent contrast agent for imaging of
the nanoparticles, ATTO647N, and an oxygen-sensing, palladium-
porphyrin based photosensitizer (Pd-porphyrin; PdTPP) for
photodynamic therapy (PDT) in the silica framework of the MSNs
and in the MSN’s nanochannels, respectively. Finally, cRGDyK
peptides were conjugated to the outer surfaces to target the
overexpressed avb3 integrins of the cancer cells (Figure 5). Cellular
uptake experiments were conducted with two tumor cell lines: MCF-7
(breast cancer), which is avb3 integrin deficient, and U87-MG
(glioblastoma), which overexpresses the avb3 integrin receptors.
Confocal fluorescence microscopy confirmed the internalization of
the RGD-labeled MSNs via receptor-mediated endocytosis. Flow
cytometric analyses revealed no significant MSN fluorescence from
the U87-MG cells pre-treated with various concentrations of the
blocking agent c(RGDyK). These results indicate the avb3 integrin-
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dependent uptake of the A647@MSN-RGD-PdTPP nanoparticles by
the U87-MG cells. Finally, the therapeutic potential of tri-functiona-
lized MSNs was confirmed using PI (propidium iodide) staining and
a WST-1 assay. These experiments showed a significant difference in
the post-irradiation cytotoxic response of the U87-MG cells that had
been treated with the targeted MNPs with respect to the cells treated
with the untargeted MNPs, while the MCF-7 cell survival wasB80%
after irradiation for the same concentration of nanoparticles.
Very recently, Ashley and colleagues reported an interesting
nanocarrier construct, the protocell (100–150 nm in diameter), that
synergistically combines features of mesoporous silica particles and
liposomes. They were synthesized by the liposome fusion to the high-
surface-area spherical silica particles.88 The protocells were decorated
with SP94 peptides (H2N-SFSIIHTPILPLGGC-COOH), which were
identified from a filamentous phage display to have an affinity for
unknown receptor(s) expressed by human hepatocellular carcinoma
(HCC), and with 0.500 wt% of a histidine-rich fusogenic peptide
(H5WYG), which promotes the endosomal escape of the protocells
and the cytosolic dispersion of the encapsulated cargo. The
nanoporous support resulted in greater stability and in enhanced
lateral bilayer fluidity compared with both liposomes and non-porous
particles, thereby promoting multivalent interactions between the
protocell and the target cancer cell using a minimal number of
targeting peptides via peptide recruitment to the cell surface.
Protocells composed largely of DOPC and loaded with fluorescent
probes (calcein, an Alexa Fluor 647-labeled dsDNA oligonucleotide, a
red fluorescent protein and Cd/Se quantum dots) and with a
chemotherapeutic drug (Dox) have a high specific affinity (Kd
o1 nM) for HCC cells, and, over the range of 6–2 peptides per
particle, their Kd values are consistently low (0.94–0.08 nM) and
relatively independent of the peptide density. Protocells, owing to the
high surface area and to the porosity of their nanoporous cores, have
an 1000 times higher capacity for Dox than similarly sized liposomes
(loaded through an ammonium phosphate gradient-based approach)
and can be engineered to release nearly 90% of their encapsulated
Dox in a bioactive form using endocytosis onto HCC. Additionally,
DOPC protocells exhibit long-term stability when maintained in a
simulated body fluid (pH of 7.4) at 37 1C, while exposing protocells
to a buffer with a pH of 5.0 promoted the rapid release of drugs (99%
within 12h). Cell viability tests indicated that the Dox-loaded
protocell treatment maintained greater than 90% normal hepatocyte
viability while killing nearly 97% of the MDR1þ hepatocellular
carcinoma (Hep3B). In contrast, Dox-loaded liposomes or protocells
without fluidity on their surface were less efficient at killing Hep3B
and caused considerable cytotoxicity to non-cancerous cells. The
Dox-loaded protocells demonstrated good therapeutic ability com-
pared with both the free Dox and Dox-loaded liposomes.
CONCLUSIONS AND FUTURE PERSPECTIVES
All of the classes of compounds described here show very interesting
properties; future developments could give promising results for the
diagnosis and therapy of many diseases, especially for cancer.
Peptide-modified nanovectors can be used to selectively carry a
drug to target cells using an imaging probe co-incorporated into the
nanovector to guide or monitor therapy. These target-selective
theranostic agents represent a new frontier in cancer therapy. They
are emerging as the next generation of multifunctional nanomedicine
for improving the outcome of a therapy. Compared to conventional
small molecule, nanotherapeutic systems have several potential
advantages: they can remain in circulation for an extended period
of time when injected intravenously and present a high payload
capacity, reduced toxicity to healthy tissue, and improved antitumor
efficacy. Theranostic agents based on nanovectors and decorated with
targeted peptides are classified according their composition and their
shape and size: liposomes, naposomes, micelles, polymeric micelles
and micelles built around a solid core. Until now, only a few examples
for each class of peptide-targeted theranostics have been developed,
most of them targeting the integrin receptors; for these very promising
compounds, effort should be put into the search for other peptide
sequences to decorate nanovector theranostics. Nevertheless, theranos-
tic formulations present several interesting advantages, although their
clinical applications could require a fundamental reengineering of the
selling and marketing processes to ensure the successful diffusion of
the theranostics prior to or in parallel with therapy.
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